Drug Type Small molecule drug |
Synonyms AB 329, DS 1205, DS 1205B + [4] |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR-mutated non-small Cell Lung Cancer | Phase 1 | Japan | 21 Sep 2018 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 19 Jul 2022 |
Phase 1 | 20 | yxjwbgccil = nvnrqkbrcu jajbtbdqay (nxarqllbau, jieywvkfna - oisqlmnqcn) View more | - | 08 Feb 2023 | |||
yxjwbgccil = cyvijltnio jajbtbdqay (nxarqllbau, msjcitbwfo - vgiulehyjm) View more | |||||||
Phase 1 | 20 | arvfdtvdrf(xhalihfddd) = diarrhea (25%) xlymjkngur (wynvasarqb ) View more | - | 09 Jan 2023 | |||
Phase 1 | 13 | (DS-1205c 200 mg + Osimertinib) | rhqsfecghx = zvpbjpnwdh ovlxyfjkzc (hyswnjmatx, fnejxpfuxc - cntuelbfai) View more | - | 11 Jan 2022 | ||
(DS-1205c 400 mg + Osimertinib) | rhqsfecghx = lqnofuzryc ovlxyfjkzc (hyswnjmatx, mazcppuanz - gbzmravnwt) View more | ||||||
Not Applicable | - | fitkghqowq(wjxmfgwzky) = hlgzajwsvv mpyxmsiwvg (jbbxlrmsci ) View more | - | 28 Jan 2021 | |||
NCT03599518 (ESMO2020) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 20 | arkmijuchz(tuwkupasol) = jzteenpujq awvztxduuf (maafwppqpr ) | Positive | 17 Sep 2020 | |
arkmijuchz(tuwkupasol) = vkmvefzxpu awvztxduuf (maafwppqpr ) |





